Why the study?
Pulmonary arterial hypertension is a severe, progressive condition with limited treatments, motivating the development of novel IP receptor agonists.
Does compound 6c-14S improve antiaggregatory activity and pharmacokinetic properties compared to MRE-269 in preclinical models?
Does compound 6c-14S improve antiaggregatory activity and pharmacokinetic properties compared to MRE-269 in preclinical models?
The novel IP receptor agonist 6c-14S shows significantly improved potency and half-life compared to MRE-269, suggesting potential for further therapeutic development in pulmonary arterial hypertension.
Leaves open clinical translation in PAH; extends SAR for selective IP agonists.
Pulmonary arterial hypertension (PAH) is a severe, progressive condition with limited treatments. This study focuses on developing novel IP receptor agonists for PAH therapy. By modifying MRE-269, a highly selective IP receptor agonist, we designed and synthesized 2-cyclic amino-5,6-diphenylpyrazine derivatives. Systematic evaluation revealed that introducing a dimethyl group at the C3 position of the piperidine ring significantly improved antiaggregatory activity. The optimal compound 6c-14S demonstrated a 40-fold increase in potency compared to MRE-269. Docking studies confirmed its high selectivity for the IP receptor, and pharmacokinetic studies showed a 3-fold improvement in half-life, suggesting its potential for therapeutic development.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: